Intranasal delivery of rapid-onset antidepressants: a new trend of treating major depressive disorder

doi:10.5246/jcps.2020.08.049

Abstract

Abstract:

Existing antidepressants seem to have an onset time of several weeks. However, newly found depression-related receptors and pathways may enlighten us to find more rapid-onset antidepressants, in which ketamine is one of the most potential antidepressants. By intranasal administration, drugs can be directly delivered to the brain via olfactory nerve route, which is proved to be suitable for some antidepressants. Well-designed rapid-onset antidepressants are the urgent requirements of the patients with depression. Intranasal administration, as a potential strategy to deliver antidepressants to brain, can improve drug efficacy and largely shorten the onset time. In this article, we sorted out some new formulation approaches in treating depression with different mechanisms and pathways compared with traditional treating strategies, along with new findings in clinical studies, proving that the combination of rapid-onset antidepressants with intranasal delivery will lead a new trend in treating depression.

Key words: Major depressive disorder, NMDA receptor, Olfactory nerve route, Antidepressants, Intranasal

CLC Number:

Supporting:

Yuqi Xie, Yushun Dou, Yue Tang. Intranasal delivery of rapid-onset antidepressants: a new trend of treating major depressive disorder[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 515-527.

References

[1] Collins, P.Y.; Patel, V.; Joestl, S.S.; March, D.; Insel, T.R.; Daar, A.S. Grand challenges in global mental health. Nature. 2011, 475, 27-30.

[2] Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 2006, 163, 1905-1917.

[3] Canuso, C.M.; Singh, J.B.; Fedgchin, M.; Alphs, L.; Lane, R.; Lim, P.; Pinter, C.; Hough, D.; Sanacora, G.; Manji, H.; Drevets, W.C. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry. 2018, 175, 620-630.

[4] Trivedi, M.H.; Rush, A.J.; Wisniewski, S.R.; Nierenberg, A.A.; Warden, D.; Ritz, L.; Norquist, G.; Howland, R.H.; Lebowitz, B.; McGrath, P.J.; Shores-Wilson, K.; Biggs, M.M.; Balasubramani, G.K.; Fava, M.; STAR|D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry. 2006, 163, 28-40.

[5] Zhou, Q.; Sheng, M. NMDA receptors in nervous system diseases. Neuropharmacology. 2013, 74, 69-75.

[6] Isaacson, J.S.; Murphy, G.J. Glutamate-mediated extrasynaptic inhibition: direct coupling of NMDA receptors to Ca(2+)-activated K+ channels. Neuron. 2001, 31, 1027-1034.

[7] Faber, E.S.; Delaney, A.J.; Sah, P. SK channels regulate excitatory synaptic transmission and plasticity in the lateral amygdala. Nat. Neurosci. 2005, 8, 635-641.

[8] Yang, Y.; Cui, Y.H.; Sang, K.N.; Dong, Y.Y.; Ni, Z.Y.; Ma, S.S.; Hu, H.L. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018, 554, 317-322.

[9] Skolnick, P. Antidepressants for the new millennium. Eur. J. Pharmacol. 1999, 375, 31-40.

[10] Skolnick, P. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino. Acids. 2002, 23, 153-159.

[11] Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 2000, 47, 351-354.

[12] Chaturvedi, H.K.; Chandra, D.; Bapna, J.S. Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression. Indian J. Exp. Biol. 1999, 37, 952-958.

[13] Feifel, D.; Malcolm, B.; Boggie, D.; Lee, K. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. J. Affect. Disord. 2017, 221, 283-288.

[14] Hashimoto, K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61, 105-123.

[15] Maeng, S.; Zarate, C.A. Jr, Du, J.; Schloesser, R.J.; McCammon, J.; Chen, G.; Manji, H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry. 2008, 63, 349-352.

[16] Tizabi, Y.; Bhatti, B.H.; Manaye, K.F.; Das, J.R.; Akinfiresoye, L. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience. 2012, 213, 72-80.

[17] Machado-Vieira, R.; Zanetti, M.V.; Teixeira, A.L.; Uno, M.; Valiengo, L.L.; Soeiro-de-Souza, M.G.; Oba-Shinjo, S.M.; de Sousa, R.T.; Zarate, C.A. Jr, Gattaz, W.F.; Marie, S.K. Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. Eur. Neuropsychopharmacol. 2015, 25, 468-473.

[18] Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21-35.

[19] Jernigan, C.S.; Goswami, D.B.; Austin, M.C.; Iyo, A.H.; Chandran, A.; Stockmeier, C.A.; Karolewicz, B. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuro - Psychopharmacol. Biol. Psychiatry. 2011, 35, 1774-1779.

[20] Li, N.X.; Lee, B.; Liu, R.J.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X.Y.; Aghajanian, G.; Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010, 329, 959-964.

[21] Yang, C.; Zhou, Z.Q.; Gao, Z.Q.; Shi, J.Y.; Yang, J.J. Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol. Psychiatry. 2013, 73, e35-e36.

[22] Yu, J.J.; Zhang, Y.; Wang, Y.; Wen, Z.Y.; Liu, X.H.; Qin, J.; Yang, J.L. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology. (Berl.) 2013, 225, 361-372.

[23] Lu, Y.; Wang, C.; Xue, Z.C.; Li, C.L.; Zhang, J.F.; Zhao, X.; Liu, A.M.; Wang, Q.W.; Zhou, W.H. PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the Hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int. J. Neuropsychopharmacol. 2014, 18, pyu110.

[24] Yang, C.; Hu, Y.M.; Zhou, Z.Q.; Zhang, G.F.; Yang, J.J. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups. J. Med. Sci. 2013, 118, 3-8.

[25] Spencer, R.L.; Deak, T. A users guide to HPA Axis research. Physiol. Behav. 2017, 178, 43-65.

[26] Herman, J.P.; Cullinan, W.E. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical Axis. Trends Neurosci. 1997, 20, 78-84.

[27] Herman, J.P. Regulation of adrenocorticosteroid receptor mRNA expression in the central nervous system. Cell Mol. Neurobiol. 1993, 13, 349-372.

[28] Morris, M.C.; Compas, B.E.; Garber, J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin. Psychol. Rev. 2012, 32, 301-315.

[29] MacHado-Vieira, R.; Soeiro-De-souza, M.G.; Richards, E.M.; Teixeira, A.L.; Zarate, C.A.Jr. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach. World J. Biol. Psychiatry. 2014, 15, 84-95.

[30] Musazzi, L.; Treccani, G.; Mallei, A.; Popoli, M. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol. Psychiatry. 2013, 73, 1180-1188.

[31] O‘Keane, V.; Frodl, T.; Dinan, T.G. A review of Atypical depression in relation to the course of depression and changes in HPA Axis organization. Psychoneuroendocrinology. 2012, 37, 1589-1599.

[32] Tringali, G.; Lisi, L.; De Simone, M.L.; Aubry, J.M.; Preziosi, P.; Pozzoli, G.; Navarra, P. Effects of olanzapine and quetiapine on corticotropin-releasing hormone release in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009, 33, 1017-1021.

[33] Matsumoto, M.; Hikosaka, O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature. 2007, 447, 1111-1115.

[34] Ji, H.; Shepard, P.D. Lateral habenula stimulation inhibits rat midbrain dopamine neurons through a GABAA receptor-mediated mechanism. J. Neurosci. 2007, 27, 6923-6930.

[35] Shumake, J.; Edwards, E.; Gonzalez-Lima, F. Opposite metabolic changes in the habenula and ventral tegmental area of a genetic model of helpless behavior. Brain Res. 2003, 963, 274-281.

[36] Grace, A.A.; Floresco, S.B.; Goto, Y.; Lodge, D.J. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 2007, 30, 220-227.

[37] Cui, Y.H.; Yang, Y.; Ni, Z.Y.; Dong, Y.Y.; Cai, G.H.; Foncelle, A.; Ma, S.S.; Sang, K.N.; Tang, S.Y.; Li, Y.Z.; Shen, Y.; Berry, H.; Wu, S.X.; Hu, H.L. Astroglial Kir4.1 in the lateral habenula drives neuronal bursts in depression. Nature. 2018, 554, 323-327.

[38] Sartorius, A.; Kiening, K.L.; Kirsch, P.; von Gall, C.C.; Haberkorn, U.; Unterberg, A.W.; Henn, F.A.; Meyer-Lindenberg, A. Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol. Psychiatry. 2010, 67, e9-e11.

[39] Lochhead, J.J.; Thorne, R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 2012, 64, 614-628.

[40] Erdő, F.; Bors, L.A.; Farkas, D.; Bajza, Á.; Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018, 143, 155-170.

[41] Crowe, T.P.; Greenlee, M.H.W.; Kanthasamy, A.G.; Hsu, W.H. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018, 195, 44-52.

[42] Huge, V.; Lauchart, M.; Magerl, W.; Schelling, G.; Beyer, A.; Thieme, D.; Azad, S.C. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur. J. Pain. 2010, 14, 387-394.

[43] Salvadore, G.; Singh, J.B. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci. Ther. 2013, 19, 428-436.

[44] Zarate, C.A. Jr, Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry. 2006, 63, 856-864.

[45] Murrough, J.W.; Perez, A.M.; Pillemer, S.; Stern, J.; Parides, M.K.; aan het Rot, M.; Collins, K.A.; Mathew, S.J.; Charney, D.S.; Iosifescu, D.V. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry. 2013, 74, 250-256.

[46] Autry, A.E.; Adachi, M.; Nosyreva, E.; Na, E.S.; Los, M.F.; Cheng, P.F.; Kavalali, E.T.; Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011, 475, 91-95.

[47] Mathew, S.J.; Shah, A.; Lapidus, K.; Clark, C.; Jarun, N.; Ostermeyer, B.; Murrough, J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012, 26, 189-204.

[48] Lapidus, K.A.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Parides, M.K.; Soleimani, L.; Feder, A.; Iosifescu, D.V.; Charney, D.S.; Murrough, J.W. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry. 2014, 76, 970-976.

[49] Naidoo, V.; Mdanda, S.; Ntshangase, S.; Naicker, T.; Kruger, H.G.; Govender, T.; Naidoo, P.; Baijnath, S. Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administraion. J. Psychiatr. Res. 2019, 112, 7-11.

[50] Kohrs, R.; Durieux, M.E. Ketamine: teaching an old drug new tricks. Anesth. Analg. 1998, 87, 1186-1193.

[51] Singh, J.B.; Fedgchin, M.; Daly, E.; Xi, L.W.; Melman, C.; De Bruecker, G.; Tadic, A.; Sienaert, P.; Wiegand, F.; Manji, H.; Drevets, W.C.; van Nueten, L. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol. Psychiatry. 2016, 80, 424-431.

[52] Ochs-Ross, R.; Daly, E.J.; Zhang, Y.; Lane, R.; Lim, P.; Morrison, R.L.; Hough, D.; Manji, H.; Drevets, W.C.; Sanacora, G.; Steffens, D.C.; Adler, C.; McShane, R.; Gaillard, R.; Wilkinson, S.T.; Singh, J.B. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am. J. Geriatr. Psychiatry. 2020, 28, 121-141.

[53] Haque, S.; Md, S.; Fazil, M.; Kumar, M.; Sahni, J.K.; Ali, J.; Baboota, S. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr. Polym. 2012, 89, 72-79.

[54] Alam, M.I.; Baboota, S.; Ahuja, A.; Ali, M.; Ali, J.; Sahni, J.K.; Bhatnagar, A. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int. J. Pharm. 2014, 470, 99-106.

[55] Nakao, Y.; Horiguchi, M.; Nakamura, R.; Sasaki-Hamada, S.; Ozawa, C.; Funane, T.; Ozawa, R.; Oka, J.I.; Yamashita, C. LARETH-25 and β-CD improve central transitivity and central pharmacological effect of the GLP-2 peptide. Int. J. Pharm. 2016, 515, 37-45.

[56] Sasaki-Hamada, S.; Nakamura, R.; Nakao, Y.; Akimoto, T.; Sanai,, Nagai, M.; Horiguchi, M.; Yamashita, C.; Oka, J.I. Antidepressant-like effects exerted by the intranasal administration of a glucagon-like peptide-2 derivative containing cell-penetrating peptides and a penetration-accelerating sequence in mice. Peptides. 2017, 87, 64-70.

[57] Paslakis, G.; Blum, W.F.; Deuschle, M. Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression. Med. Hypotheses. 2012, 79, 222-225.

[58] Thorne, R.G.; Pronk, G.J.; Padmanabhan, V.; Frey, W.H. 2nd Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004, 127, 481-496.

[59] MacDonald, K.; MacDonald, T.M.; Brüne, M.; Lamb, K.; Wilson, M.P.; Golshan, S.; Feifel, D. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology. 2013, 38, 2831-2843.

[60] Naidoo, V.; Mdanda, S.; Ntshangase, S.; Naicker, T.; Kruger, H.G.; Govender, T.; Naidoo, P.; Baijnath, S. Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administraion. J. Psychiatr. Res. 2019, 112, 7-11.